USA

The acquisition adds two key products to BioStem’s portfolio: Neox and Clarix, both cryopreserved amniotic membrane allografts.

Dr. Basson joins Variant Bio with more than 25 years of leadership experience spanning academic medicine, global pharmaceutical development, and biotechnology sectors.

Insilico will lead the initial phase, advancing ISM8969 through preclinical studies and into a phase 1 clinical trial for Parkinson’s disease.

The U.S. Food and Drug Administration (FDA) recently approves an updated label for UNLOXCYT based on long-term follow-up data from the pivotal CK-301-101 clinical trial.

The company recently filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for its first BFS-based prefilled injection device, achieving a major regulatory breakthrough for the platform.

This collaboration delivers crucial funding to Agenus while simultaneously securing sustained biologics manufacturing capacity within the United States.

Penumbra shareholders will have the option to receive either USD374 in cash or 3.8721 Boston Scientific shares, with the transaction structured as approximately 73% cash and 27% stock.

Caldera raised USD75 million in a Series A financing round led by Atlas Venture, LAV, and venBio, followed by an additional USD37.5 million in a Series A-1 round led by Omega Funds.

This new 35,000 square foot, purpose-built site represents Novartis’s fourth dedicated RLT facility.

Terumo plans to distribute the product to hospitals, clinics, and emergency care settings nationwide, making the technology widely accessible to medical professionals who perform injections daily.